VI Spanish Consensus Conference on the treatment of Helicobacter pylori infection
Abstract
Helicobacter pylori (H. pylori) infection is highly prevalent in the Spanish population and is the main cause of chronic gastritis, peptic ulcer disease, and gastric cancer. Five previous consensus meetings on the management of H. pylori infection in Spain have been held, the most recent in 2021. Changes in treatment regimens and the growing body of available evidence justified the organization of this VI Spanish Consensus Conference in June 2026, focused on the treatment of this infection. Sixteen experts in the field participated, performed a systematic literature search, and developed 25 recommendations, which were subsequently submitted to an iterative process of serial anonymous voting using Delphi methodology. The GRADE system was used to classify the certainty of the evidence and the strength of the recommendations. As a starting point, this consensus establishes that the recommended treatments should achieve, and preferably exceed, a 90% cure rate when administered empirically. Accordingly, quadruple regimens are recommended as both first-line and rescue treatments. As first-line treatment, a 10-day regimen with a proton pump inhibitor plus bismuth, tetracycline, and metronidazole (Pylera®) is recommended. After failure of this regimen, a combination of a proton pump inhibitor, amoxicillin, levofloxacin, and bismuth is recommended. This consensus also provides a detailed review of other rescue treatment alternatives.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.